Biomea Fusion, Inc. (BMEA) compared with its closest peers (CPIX, COYA, RFL, PLYX, FBIO). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Cumberland Pharmaceuticals Inc. (CPIX) | $114.10M | -20.5 |
| Coya Therapeutics, Inc. (COYA) | $114.01M | -4.6 |
| Rafael Holdings, Inc. (RFL) | $109.89M | -1.6 |
| Polaryx Therapeutics, Inc. Common Stock (PLYX) | $103.68M | — |
| Fortress Biotech, Inc. (FBIO) | $95.44M | 0.9 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV) | $94.59M | -1.2 |
| Aldeyra Therapeutics, Inc. (ALDX) | $91.69M | -9.2 |
| Rallybio Corporation (RLYB) | $89.22M | -0.4 |
| Gain Therapeutics, Inc. (GANX) | $87.29M | -5.3 |
| Adicet Bio, Inc. (ACET) | $85.86M | -0.5 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
BMEA overview · BMEA earnings · BMEA financials · BMEA KPIs · BMEA investor relations · BMEA ownership · BMEA filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.